These results provide insights into how SCC cells escape immunological surveillance, and suggest targeting IFNγ-TP63/STAT1 axis as a potential strategy to improve anti-tumor immunotherapeutic effect and overcome ICB resistance of SCCs. The gene discussed is TP63; the disease is neoplasm.